Trials / Completed
CompletedNCT00041990
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
A Phase II, Multicenter Study of Decitabine (5-Aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Accelerated Phase Refractory to Imatinib Mesylate (STI 571)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Astex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | decitabine (5-aza-2'deoxycytidine) |
Timeline
- Start date
- 2002-07-01
- First posted
- 2002-07-23
- Last updated
- 2007-12-17
Locations
8 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00041990. Inclusion in this directory is not an endorsement.